Rupa Jayagopal
Podiatrist · Birmingham, ALNPI 1902292873
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Stryker accounts for 69.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $526, 3.1 times the $171 reported in 2022. That places this record below the midpoint for podiatrist clinicians in AL, where the typical reported total is $1,120.
Across 29 payments — averaging $33.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$673
- Convatec Inc.$165
- Organogenesis Inc.$34
- Paratek Pharmaceuticals, Inc.$30
- Amgen$21
- Bioventus LLC$20
- plus $28 from 2 others
What the payments were for
- Food & beverage$972100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 15 | $673 |
| Convatec Inc. | 7 | $165 |
| Organogenesis Inc. | 1 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Amgen | 1 | $21 |
| Bioventus LLC | 1 | $20 |
| Boston Scientific | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$972 in reported general payments places this provider in the 45th percentile of 59 podiatrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 94 | $1,736 |
| Naftifine Hcl | 12 | $1,611 |
| Mupirocin | 38 | $300 |
| Ketoconazole | 11 | $187 |
| Methylprednisolone | 18 | $161 |
| Cephalexin | 12 | $71 |
| Meloxicam | 12 | $13 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Birmingham
- John RobersonBirmingham$10K
- Kyle MaukBirmingham$10K
- Brent HaverstockBirmingham$7K
- David LindeBirmingham$6K
- Jamie ClecklerBirmingham$5K
- Maurice WainwrightBirmingham$2K
- John CalcateraBirmingham$1K
- Kevin WaldropBirmingham$556
- Mark GotfrydBirmingham$428
- Mark KunkelBirmingham$111
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.